Pharm-D Health Science

What Pharm-D Health Science does

Pharm-D Health Science Berhad is a Malaysian specialty pharmaceutical and healthcare group headquartered in Kuala Lumpur with a regional presence in Singapore, operating across the full pharmaceutical value chain from research and development through manufacturing, marketing, and distribution. Founded in 2001 by a group of pharmacists to address unmet needs in niche and underserved patient populations, the company has built a diversified portfolio spanning prescription medicines, over-the-counter products, medical nutrition, health supplements, probiotics, postbiotics, medical devices, and skincare. Its proprietary technology platform includes the patented Lassica K014 postbiotic ingredient (Patent PI 2022005512) derived from a proprietary Lactobacillus plantarum K014 strain developed by its wholly-owned biotech subsidiary Biotenova Sdn Bhd, the Vutycid calcium butyrate formulation targeting IBS and IBD, and the VALENS Onthera+ immunonutrition formula for cancer-related malnutrition.

The company operates through multiple branded sub-businesses including VALENS (medical nutrition for rare diseases, cancer, bariatric, and elderly care), ELDON (consumer wellness products including the Malaysia Book of Records-recognized MAGELAX magnesium glycinate), Lang Bragman (Malaysia's largest range of home-grown probiotic products with 34+ formulations acquired via the 2021 merger with Attivo Healthcare), MedSkin (skincare), and the Pharm-Dx digital health platform. Distribution reaches over 2,000 retail pharmacies and 100+ clinics across Malaysia and Singapore, supplemented by direct hospital supply to government and private institutions including Hospital Kuala Lumpur and Avisena Healthcare. Research collaborations are maintained with Malaysian universities (USM, UPM, IMU, Monash University Malaysia) and internationally with Jiangnan University in China.

The business model is anchored in pharmaceutical and consumer health product sales across prescription and OTC channels, specialty medical nutrition, and genetic diagnostics distribution via the AGTC Genomics partnership. Revenue is generated through pharmacy chain distribution (BIG CARiNG Group including BIG Pharmacy, CARiNG Pharmacy, and others), hospital procurement, and direct-to-consumer e-commerce through Pharm-Dx, with institutional and channel-based pricing rather than publicly disclosed pricing. The company serves a vertical segmentation of patient and consumer use cases including rare disease patients, cancer patients, individuals with chronic conditions, healthcare providers, and general wellness consumers, with strategic emphasis on supply chain resilience through local manufacturing to reduce import dependencies.

Name

Pharm-D Health Science

Legal name

Pharm-D Health Science Berhad

Website

https://pharmdhs.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

51–100 employees

Short description

Pharm-D Health Science is a Malaysian specialty pharmaceutical and healthcare group that develops, manufactures, and distributes medical nutrition, probiotics, postbiotics, and niche medicines for rare disease, oncology, and consumer health segments across Malaysia and Singapore through 2,000+ pharmacies and hospital channels.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals and Medical Nutrition

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD), Specialty Pharmacy & Biologics Distribution (CRAOAHAD), Pharmacy & Health Essentials Delivery (CRAFAFAI)

Keywords

• Specialty pharmaceuticals
• Medical nutrition products
• Probiotic formulations
• Postbiotic ingredients
• Rare disease medicines

Headquarters

HQ city

Kuala Lumpur

HQ country

Malaysia

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Prescription Medicines: Specialty and niche pharmaceuticals including rare disease medications, hospital-only medications, and highly-specialised therapies with complex handling requirements.
2. Over-the-Counter (OTC) Products: Non-prescription health products distributed through pharmacy chains and retail outlets.
3. Specialized Medical Nutrition: VALENS brand medical nutrition products for rare diseases, cancer care, post-surgery recovery, weight management, and elderly care, including VALENS Onthera+, Vutycid, and specialized formulations for metabolic disorders.
4. Health Supplements and Nutraceuticals: Probiotic products (Lang Bragman - 34+ formulations), postbiotic products, magnesium glycinate supplements (ELDON DX MAGELAX), and wellness products distributed through pharmacies and retail channels.
5. Medical Devices: Medical devices and skincare products under brands including MedSkin and other healthcare solutions.
6. Genetic Diagnostic Services: Genetic screening and precision medicine services through AGTC Genomics partnership, expanding into diagnostic tests complementing pharmaceutical products.

Pricing tiers

Go-to-market motion4 records

Distribution channels5 records

Marketing channels7 records

Core offering

Pharm-D Health Science is a Malaysian specialty pharmaceutical and healthcare group that manufactures, markets, and distributes prescription medicines, over-the-counter products, specialized medical nutrition (VALENS), health supplements and nutraceuticals (ELDON, Lang Bragman), medical devices, and skincare. The company operates its own R&D and manufacturing capabilities (via Biotenova and GMP-certified facilities) and sells through pharmacy chains, hospitals, clinics, and its own digital platform across Malaysia and Singapore.

Product overview

Pharm-D Health Science is a diversified Malaysian pharmaceutical and consumer health group offering a comprehensive portfolio of health brands and products. The core offering spans specialized medicines, medical nutrition (VALENS), health supplements (ELDON, Lang Bragman), and skincare (MedSkin). VALENS provides medical nutrition for rare diseases, cancer care (Onthera+), and gastrointestinal health (Vutycid). ELDON focuses on wellness supplements with flagship product ELDON DX MAGELAX for sleep support. Lang Bragman offers Malaysia's largest range of probiotic products with 34+ formulations. Additional brands include Reflux-G, Retane, and CMD. The company operates through Pharm-Dx digital platform and maintains R&D capabilities through Biotenova for postbiotics innovation. Distribution spans over 2,000 pharmacies in Malaysia and Singapore.

Differentiator

Problem solved

Functional benefit

Brands

• VALENS: Medical nutrition brand for therapeutic, healing and recovery purposes including post-surgery recovery, weight management, elderly care, rare diseases, cancer nutrition (Onthera+), and gut health (Vutycid)
• ELDON
• Lang Bragman
• MedSkin
• CMD
• Reflux-G
• Retane
• X-Temp
• JARANG

Products and services

• VALENS Medical Nutrition Range Specialized medical nutrition brand offering therapeutic nutritional products for rare diseases, cancer care, post-surgery recovery, weight management, and elderly care. Includes Onthera+ for cancer malnutrition and Vutycid for IBS/IBD. Distributed through hospital channels and specialty pharmacies in Malaysia and Singapore.
• VALENS Onthera+ Comprehensive immunonutrition supplement drink designed to combat malnutrition in cancer patients and those experiencing hypercatabolic states where the body breaks down muscle tissue at accelerated rates. The product was the result of years of dedicated research and development to improve patient outcomes.
• VALENS Vutycid First-ever calcium butyrate formulation designed to target irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Launched at the Malaysian Dietitians' Association (MDA) symposium 2024 as part of the VALENS medical nutrition range.
• ELDON Health and Wellness Brand Health and wellness brand under Pharm-D Health Science offering science-based nutritional supplements, functional foods, skincare, personal care, and medical-related products. Available in Malaysia and Singapore through over 2,000 retail pharmacies and 100+ clinics.
• ELDON DX MAGELAX Magnesium glycinate supplement capsule for sleep, stress management, and lifestyle balance. Entered the Malaysian market in 2020 as one of the earliest NPRA-registered glycine magnesium supplements and achieved Malaysia Book of Records recognition for most magnesium glycinate capsules sold in Malaysia.
• Lang Bragman Probiotic Series Probiotic specialty brand with over 34 formulations catering to various health needs including Pyloress, Infabac, and Femiclear. Recognized as Malaysia's largest range of home-grown probiotic products by Malaysia Book of Records. Products use patented probiotic strains and are manufactured in GMP-certified and Halal-compliant facilities.
• X-Temp Oral Suspension System Specialized oral suspension compounding vehicle formulated to assist custom preparation of oral liquid, non-soluble (suspended), and aqueous dosage forms. Used in paediatric care and extemporaneous preparation for accurate dosing and enhanced palatability, with hands-on workshops conducted with pharmacy students.
• Pharm-Dx Digital Health Platform Digital health platform providing direct access to quality medical nutrition and nutraceutical solutions. Operates as an online storefront for purchasing health products and accessing health information, complementing the group's pharmacy and hospital distribution channels.
• Genetic Diagnostic Services Genetic screening and precision medicine services distributed through a strategic partnership with AGTC Genomics, providing sophisticated genetic diagnostic tests for healthcare providers. Combines next-generation sequencing (NGS) capabilities with Pharm-D's specialty medicines distribution network.
• JARANG Rare Disease Advocacy Program Corporate social responsibility initiative aimed at raising awareness, providing support, and empowering individuals and families affected by rare diseases in Malaysia. Collaborates with hospitals including Hospital Kuala Lumpur, patient advocacy groups such as the Malaysian Rare Disorders Society, and healthcare professionals.

Quantifiable outcome

• Lang Bragman recognized as largest range of home-grown probiotic products in Malaysia with 34+ formulations
• +2 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• National Cancer Society Malaysia (NCSM)coreStrategic or Co-development Partner · 4 February 2026Collaboration established NCSM-PDHS VALENS Support Fund to strengthen cancer care through improved access to specialized nutrition product support, education and awareness. Includes Onthera+ 1,000 Cans of Hope donation and ongoing portion of VALENS sales allocated to NCSM.
• BIG CARiNG GroupcoreChannel Partner/ Reseller/ Distributor · 10 December 2025Distribution partnership for Lang Bragman probiotic products through BIG CARiNG Group pharmacy chains (BIG Pharmacy, CARiNG Pharmacy, Georgetown Pharmacy, Ting Pharmacy, Wellings Pharmacy) across Malaysia and Singapore.
• Hospital Kuala LumpurcoreStrategic or Co-development Partner · 28 February 2025Pharm-D Health Science collaborated with Hospital Kuala Lumpur's Department of Genetics as main sponsor for Rare Disease Day 2025 celebrations. The partnership includes support for rare disease awareness, genetic testing sponsorship (RM75,000 worth of WES tests), and publication of educational books for patients and caregivers.
• Malaysian Rare Disorders SocietycoreStrategic or Co-development Partner · 28 February 2025Collaboration with patient advocacy group for rare disease awareness and support as part of JARANG Program, Pharm-D's CSR initiative for rare disease community empowerment.
• AGTC GenomicscoreChannel Partner/ Reseller/ Distributor · 29 November 2024Strategic distributorship agreement to enhance availability and accessibility of genetic screening for precision medicine in Malaysia. Combines AGTC Genomics' expertise in next-generation sequencing (NGS) with Pharm-D's extensive supply chain network of specialty medicines.
• IDDSI CommitteecoreStrategic or Co-development Partner · 29 November 2024Pharm-D served as Festival Secretariat for Asia IDDSI Festival 2024, a specialized platform dedicated to promoting safe eating and drinking for individuals with dysphagia using the globally recognized IDDSI framework.
• Universiti Putra Malaysia (UPM)coreStrategic or Co-development Partner · 13 September 2024Research partnership through Biotenova Sdn Bhd focusing on 'The Role of Postbiotics (Lassica K014™) in Inflammatory Skin Disorders' to develop treatments for eczema, psoriasis, and dermatitis.
• Universiti Sains Malaysia (USM)coreStrategic or Co-development Partner · 1 April 2024Clinical research collaboration with USM's School of Pharmaceutical Science and School of Industrial Technology for groundbreaking postbiotic study investigating effects on gut and immune health using novel probiotic strain from locally fermented food origin.
• Jiangnan University (China)minorStrategic or Co-development Partner · 1 April 2024International research collaboration for postbiotic research and innovation, contributing to Pharm-D's global research network alongside Malaysian universities.
• IMU University (International Medical University)coreStrategic or Co-development Partner · 6 March 2024Comprehensive collaboration integrating diverse educational initiatives to enhance teaching and learning experiences. Pharm-D serves as Festival Secretariat for Asia IDDSI Festival 2024 hosted at IMU, advancing dysphagia care knowledge.
• Avisena Healthcare HospitalminorStrategic or Co-development Partner · 6 March 2024VALENS participated in Bariatric Warriors Gathering 2024, a patient support workshop organized by bariatric patients at Avisena Healthcare Hospital, supporting nutrition care for bariatric patients.
• Monash University MalaysiaminorStrategic or Co-development PartnerPartnership with Monash University Pharmacy Society (MUPhaS) to host X-Temp Compounding Workshop for pharmacy students, providing practical experience with pharmaceutical compounding vehicles.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Kotra Pharma Berhad: Malaysian pharmaceutical manufacturer and marketer focusing on niche and specialty medicines; comparable business model of specialty/niche-focused pharma distribution and brand-building in Southeast Asia.
• Duopharma Biotech Berhad: Malaysian-listed pharmaceutical manufacturer with branded generics, OTC, and consumer health portfolio sold through hospital and pharmacy channels. Direct regional peer of similar scale and go-to-market in Malaysia/Singapore.
• Apex Healthcare Berhad: Pharmaceutical distribution and manufacturing group operating across Malaysia and Singapore, including hospital and retail pharmacy channels. Comparable in distribution scale and cross-border Malaysia-Singapore footprint.
• CCM Duopharma Biotech (now Duopharma): Malaysian pharmaceutical manufacturing heritage comparable to Pharm-D's niche-branded pharma focus; similar products and channel access through government hospitals and private clinics.
• Hovid Berhad: Malaysian pharmaceutical manufacturer producing generics, OTC, and health supplements; comparable in branded pharma manufacturing and distribution across Southeast Asia.

Broad incumbents

• BioGaia AB: Swedish probiotic specialist with patented Lactobacillus strains commercialised globally, comparable to Lang Bragman's strain-based probiotic franchise. Relevant peer for postbiotic/Lactobacillus IP strategy.
• Yakult Honsha: Global probiotic beverage brand with strong Malaysia/Singapore distribution and consumer recognition. Competes in the broader probiotic category where Lang Bragman operates.
• Danone Nutricia: Global medical nutrition leader (Nutrison, Fortimel) operating across Malaysia/Singapore through pharmacy and hospital channels. Competes with VALENS Onthera+ in oncology nutrition and dysphagia solutions.
• Abbott (Malaysia): Global healthcare incumbent with leading medical nutrition portfolio (Ensure, Glucerna, PediaSure). Direct comp in the medical nutrition segment where VALENS and Onthera+ compete, but Abbott offers broader scale and global R&D.

Emerging players

• PharmaEssentia Corporation: Emerging Asia-focused biotech commercialising specialty therapies including rare-disease indications. Comparable niche-specialty therapeutic focus and Asia go-to-market strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/pharmdhs
• LinkedInlinkedin.com/company/pharmdhs
• Instagraminstagram.com/pharmdhealthscience

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharm-D Health Science